Bulletin
Investor Alert

Market Pulse Archives

June 4, 2020, 3:19 a.m. EDT

Galapagos shares rise on Phase 3 studies of arthritis drug it's making with Gilead

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Galapagos N.V. (GLPG)
  • X
    Galapagos N.V. ADR (GLPG)
  • X
    Gilead Sciences Inc. (GILD)

or Cancel Already have a watchlist? Log In

By Steve Goldstein

Galapagos /zigman2/quotes/208057460/delayed NL:GLPG -3.51% /zigman2/quotes/205153380/composite GLPG -4.63% rose nearly 3% in early Amsterdam trade as Phase 3 studies of drug it's making with Gilead Sciences /zigman2/quotes/210293917/composite GILD +2.15% showed "sustained efficacy and a consistent safety profile" in treating moderately to severely active rheumatoid arthritis. The companies said they will be presenting the data on filgotinib at the European League Against Rheumatism's European E-Congress of Rheumatology 2020.

/zigman2/quotes/208057460/delayed
NL : Netherlands: Euronext Amsterdam
171.60
-6.25 -3.51%
Volume: 368,296
July 10, 2020 5:39p
P/E Ratio
65.96
Dividend Yield
N/A
Market Cap
€11.61 billion
Rev. per Employee
€481,393
loading...
/zigman2/quotes/205153380/composite
US : U.S.: Nasdaq
$ 191.77
-9.30 -4.63%
Volume: 189,418
July 10, 2020 4:00p
P/E Ratio
69.81
Dividend Yield
N/A
Market Cap
$13.11 billion
Rev. per Employee
$567,924
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 76.32
+1.61 +2.15%
Volume: 9.55M
July 10, 2020 4:00p
P/E Ratio
19.61
Dividend Yield
3.56%
Market Cap
$93.71 billion
Rev. per Employee
$2.02M
loading...

This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.